Gufic BioSciences Share Price

371.2518.06 (5.12%)

Closed
As On: 12 Jun, 2026, 03:52 PM IST
As On: 12 Jun, 2026, 03:52 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Open	355.20
High	374.90
Low	352.60
Prev Close	353.20
Volume	1,61,321
VWAP(₹)	364.47

Share Price	Value
Today/Current/Last	371.25370.85
Previous Day	353.20354.00

Gufic BioSci Share Recommendations

Recent Recos

Target₹78
OrganizationNirmal Bang Securities
BUY

View all Stock Recommendations

News & Analysis

View all Gufic BioSci Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

Income (P&L)

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	250.65	232.20	239.17	224.65	205.41
Total Income Growth (%)	7.94	-2.91	6.46	9.36	-2.02
Total Expenses	212.26	206.12	206.98	198.14	186.49
Total Expenses Growth (%)	2.98	-0.41	4.46	6.25	4.48
EBIT	38.39	26.08	32.19	26.51	18.92
EBIT Growth (%)	47.21	-18.99	21.43	40.07	-39.28
Profit after Tax (PAT)	21.90	12.42	16.82	13.07	7.72
PAT Growth (%)	76.25	-26.16	28.72	69.32	-60.01
EBIT Margin (%)	15.32	11.23	13.46	11.80	9.21
Net Profit Margin (%)	8.74	5.35	7.03	5.82	3.76
Basic EPS (₹)	2.18	1.24	1.68	1.30	0.77

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	250.86	231.89	232.51	227.81	205.40
Total Income Growth (%)	8.18	-0.27	2.06	10.91	-2.03
Total Expenses	213.79	202.48	202.40	202.30	186.22
Total Expenses Growth (%)	5.59	0.04	0.05	8.63	4.35
EBIT	37.07	29.41	30.11	25.51	19.18
EBIT Growth (%)	26.05	-2.35	18.04	33.01	-38.51
Profit after Tax (PAT)	20.57	15.56	14.94	12.07	7.97
PAT Growth (%)	32.19	4.20	23.72	51.41	-58.74
EBIT Margin (%)	14.78	12.68	12.95	11.20	9.34
Net Profit Margin (%)	8.20	6.71	6.42	5.30	3.88
Basic EPS (₹)	2.05	1.55	1.49	1.20	0.80

	FY 2026	FY 2025
Total Revenue	946.66	823.43
Total Revenue Growth (%)	14.97	1.80
Total Expenses	860.12	729.29
Total Expenses Growth (%)	17.94	5.21
Profit after Tax (PAT)	64.21	69.65
PAT Growth (%)	-7.80	-19.14
Operating Profit Margin (%)	13.04	14.47
Net Profit Margin (%)	6.80	8.49
Basic EPS (₹)	6.40	6.95

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	943.06	823.42	808.84	693.19	782.26
Total Revenue Growth (%)	14.53	1.80	16.68	-11.39	59.18
Total Expenses	857.57	728.99	693.17	586.47	655.42
Total Expenses Growth (%)	17.64	5.17	18.19	-10.52	51.12
Profit after Tax (PAT)	63.15	69.93	86.14	79.70	95.84
PAT Growth (%)	-9.70	-18.81	8.07	-16.84	116.68
Operating Profit Margin (%)	12.98	14.50	16.24	16.64	16.90
Net Profit Margin (%)	6.71	8.53	10.67	11.54	12.30
Basic EPS (₹)	6.30	6.97	8.74	8.22	9.89

All figures in Rs Cr, unless mentioned otherwise

Insights

Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 14.53% outperformed its 3 year CAGR of 10.69%. (Source: Standalone Financials)
Employee & Interest Expense
Company has spent 3.88% of its operating revenues towards interest expenses and 16.07% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2026	FY 2025
Total Assets	1,342.37	1,169.36
Total Assets Growth (%)	14.80	7.03
Total Liabilities	677.39	568.29
Total Liabilities Growth (%)	19.20	1.48
Total Equity	664.99	601.08
Total Equity Growth (%)	10.63	12.87
Current Ratio (x)	1.55	1.61
Total Debt to Equity (x)	0.58	0.52
Contingent Liabilities	0.00	6.89

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	1,341.59	1,169.63	1,092.54	861.16	521.40
Total Assets Growth (%)	14.70	7.06	26.87	65.16	32.99
Total Liabilities	677.41	568.26	559.98	513.35	252.28
Total Liabilities Growth (%)	19.21	1.48	9.08	103.48	15.40
Total Equity	664.18	601.36	532.56	347.81	269.12
Total Equity Growth (%)	10.45	12.92	53.12	29.24	55.17
Current Ratio (x)	1.55	1.61	1.61	1.61	1.72
Total Debt to Equity (x)	0.58	0.52	0.60	0.90	0.23
Contingent Liabilities	0.00	6.89	11.80	27.87	100.51

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2026	FY 2025
Net Cash flow from Operating Activities	44.97	122.57
Net Cash used in Investing Activities	-30.96	-70.78
Net Cash flow from Financing Activities	32.46	-37.20
Net Cash Flow	46.46	14.59
Closing Cash & Cash Equivalent	62.19	15.72
Closing Cash & Cash Equivalent Growth (%)	295.50	1,283.12
Total Debt/ CFO (x)	8.57	2.53

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	44.02	122.78	-7.46	-26.59	104.44
Net Cash used in Investing Activities	-30.96	-71.79	-102.40	-190.73	-95.94
Net Cash flow from Financing Activities	32.36	-37.20	82.38	234.31	-3.10
Net Cash Flow	45.42	13.78	-27.48	16.99	5.41
Closing Cash & Cash Equivalent	60.32	14.91	1.13	28.60	11.61
Closing Cash & Cash Equivalent Growth (%)	304.63	1,223.58	-96.06	146.40	87.19
Total Debt/ CFO (x)	8.75	2.53	-42.51	-11.71	0.59

All figures in Rs Cr, unless mentioned otherwise

Insights

Cash from Operations vs PAT
Operating cash flow of Rs 44.97 cr is 0.7 times compared to the reported net profit of Rs 64.21 cr. (Source: Consolidated Financials)
Decrease in Cash from Investing
Company has used Rs 30.96 cr for investing activities which is an YoY decrease of 56.25%. (Source: Consolidated Financials)

View Details

Ratios

Annual	FY 2026	FY 2025
Return on Equity (%)	9.65	11.58
Return on Capital Employed (%)	14.93	15.17
Return on Assets (%)	4.78	5.95
Interest Coverage Ratio (x)	4.21	5.70
Asset Turnover Ratio (x)	0.75	0.72
Price to Earnings (x)	42.92	48.54
Price to Book (x)	4.14	5.61
EV/EBITDA (x)	19.89	26.16
EBITDA Margin (%)	16.31	17.04

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	9.50	11.62	16.17	22.91	35.61
Return on Capital Employed (%)	14.82	15.20	18.18	20.06	39.37
Return on Assets (%)	4.70	5.97	7.88	9.25	18.38
Interest Coverage Ratio (x)	4.18	5.71	9.64	16.69	30.70
Asset Turnover Ratio (x)	0.75	0.72	0.83	1.00	1.71
Price to Earnings (x)	43.67	48.31	33.00	22.73	25.19
Price to Book (x)	4.15	5.61	5.33	5.20	8.97
EV/EBITDA (x)	20.04	26.11	21.23	15.12	16.45
EBITDA Margin (%)	16.26	17.07	18.35	19.86	19.10

Insights

Passing Profits to Shareholders
Company has consistently declining ROE in last 5 years. Majority of profits last year were disbursed as dividends to shareholders. (Source: Standalone Financials)

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Gufic BioSci	57.98	5.60	9.65	14.93	4.78	10.83	13.04	6.80	6.40	1.55	0.58	8.57
Orchid Pharma	228.53	3.61	1.59	2.50	1.07	7.22	5.03	2.61	4.05	2.45	0.28	3.53
Gujarat Themis	90.40	14.66	16.22	15.32	9.27	2.74	39.22	28.15	4.28	1.12	0.56	3.28
IOL Chemicals	28.63	2.19	7.65	11.07	5.32	1.42	9.06	5.93	4.69	1.78	0.07	0.62
RPG Life Sci	31.83	6.06	19.02	23.89	14.52	12.17	21.36	16.27	69.64	3.52	0.03	0.35
Add More

Annual Ratios (%)

Choose from Peers

Aarti Drugs
Unichem Labs
Solara Active Pharma
Dishman Carbogen
Morepen Labs

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Gufic BioSci Stock Performance	5.12	29.58	27.67	28.66	-0.96	82.43	86.09
Orchid Pharma Stock Performance	8.42	27.51	65.29	37.26	24.28	116.30	-38.13
Gujarat Themis Stock Performance	1.05	3.83	17.07	15.35	23.66	0.00	0.00
IOL Chemicals Stock Performance	5.01	22.76	47.14	83.09	55.60	52.15	8.16
RPG Life Sci Stock Performance	0.78	-5.61	10.91	16.44	2.11	186.47	391.94
Add More

Category	No. of Shares	Percentage	% Change QoQ
Promoters	7,27,08,151	72.50 %	0.00
Pledge	0	0.00 %	0.00
FII	4,24,492	0.42 %	-0.02
DII	38,42,684	3.83 %	0.09
MF	36,40,017	3.63 %	0.10
Others	2,33,07,179	23.25 %	-0.07

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	72.50	72.50	72.50	72.51
Pledge	0.00	0.00	0.00	0.00
FII	0.42	0.44	0.33	0.32
DII	3.83	3.73	3.66	3.38
Mutual Funds	3.63	3.53	3.48	3.38
Others	23.25	23.33	23.51	23.79

Mutual Funds Ownership

MF Ownership as on 30 April 2026

ICICI Pru Multicap Direct-G
Equity: Multi Cap
4
- 42.15
  Amount Invested (in Cr.)
- 0.24797415%
  % of AUM
- 0.00
  % Change (MoM basis)
SBI Healthcare Opportunities Direct-G
Equity: Sectoral-Pharma
5
- 20.06
  Amount Invested (in Cr.)
- 0.46%
  % of AUM
- -11.91
  % Change (MoM basis)
Bank of India Small Cap Direct-G
Equity: Small Cap
4
- 16.25
  Amount Invested (in Cr.)
- 0.75%
  % of AUM
- 0.00
  % Change (MoM basis)

View all Mutual Fund Schemes

Corporate Actions

Recent
Final
10%
May 29, 2026
Board Meeting
Audited Results & Final Dividend
May 22, 2026
Board Meeting
Quarterly Results
Feb 09, 2026

Board Meetings

Announced on	Meeting on
May 22, 2026	May 29, 2026
Audited Results & Final Dividend
Feb 09, 2026	Feb 13, 2026
Quarterly Results
Nov 07, 2025	Nov 14, 2025
Quarterly Results
Aug 07, 2025	Aug 13, 2025
Quarterly Results
May 23, 2025	May 30, 2025
Audited Results & Final Dividend

Dividends
Announced on Ex-Date Dividend%
May 30, 2025 Sep 22, 2025 10%
May 29, 2024 Sep 18, 2024 10%
May 29, 2023 Sep 21, 2023 10%
May 20, 2022 Aug 24, 2022 10%
May 29, 2026 - 10%
Bonus
Announced on Ex-Date
Oct 04, 2000 Oct 19, 2000
Bonus Ratio: 5 share(s) for every 2 shares held
Splits
Announced on Ex-Date
Sep 28, 2002 Oct 29, 2002
Split: Old FV10.0| New FV:1.0
Rights
No Data Available

Announced on	Ex-Date	Dividend%
May 30, 2025	Sep 22, 2025	10%
May 29, 2024	Sep 18, 2024	10%
May 29, 2023	Sep 21, 2023	10%
May 20, 2022	Aug 24, 2022	10%
May 29, 2026	-	10%

Announced on	Ex-Date
Oct 04, 2000	Oct 19, 2000
Bonus Ratio: 5 share(s) for every 2 shares held

Announced on	Ex-Date
Sep 28, 2002	Oct 29, 2002
Split: Old FV10.0\| New FV:1.0

AGM/EGM Meetings

Announced on	Meeting on
Sep 10, 2025	Sep 29, 2025
-
Jan 07, 2025	Feb 08, 2025
-
Sep 04, 2024	Sep 25, 2024
Rs.0.1000 per share(10%)Final Dividend & A.G.M.
Sep 13, 2023	Sep 29, 2023
Rs.0.1000 per share(10%)Final Dividend & A.G.M.
Oct 20, 2020	Nov 11, 2020
Book closure from Nov 5, 2020 to Nov 11, 2020

About Gufic BioSci

Gufic BioSciences Ltd., incorporated in the year 1984, is a Small Cap company (having a market cap of Rs 3,722.99 Crore) operating in Pharmaceuticals sector.

Gufic BioSciences Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue and Processing Charges for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 250.65 Crore, up 7.94 % from last quarter Total Income of Rs 232.20 Crore and up 22.02 % from last year same quarter Total Income of Rs 205.41 Crore. Company has reported net profit after tax of Rs 21.90 Crore in latest quarter.

The company’s top management includes Mr.Jayesh P Choksi, Mr.Pranav J Choksi, Mr.Pankaj J Gandhi, Mr.Akshya Kumar Mahapatra, Dr.Anu S Auora, Mr.Kamal K Seth, Mr.Devakinandan B Roonghta, Ms.Ami N Shah. Company has Mittal Agarwal & Co. as its auditors. As on 31-03-2026, the company has a total of 10.03 Crore shares outstanding.

Gufic BioSci Share Price Today is Rs. 371.25. On previous day, the Gufic BioSci Share Price (NSE) closed at Rs. 353.2, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 72.5% of the stake in Gufic BioSci shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Gufic BioSci stocks was 0.42% as compared to 0.44% in Dec 2025 with decrease of 0.02%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 3.83% as compared to 3.74% in Dec 2025 with increase of 0.09%. Out of the total DII holdings in Gufic BioSci shares 3.63% was held by mutual funds. The rest including public held is 23.25%. Gufic BioSci stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Gufic BioSci Dividend: Ever since 1984, Gufic BioSci dividends has been paid out around 29 times. As on 12 Jun, 2026, 03:52 PM IST, The overall dividend yield for Gufic BioSci stands at 0.03%. The last dividend paid was on September 22, 2025 (Rs. 0.1). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 6.4.

Gufic BioSci Bonus: The most recent bonus issue had been in year October 19, 2000 around 25 years ago at 2 : 5 ratio. The first bonus issue was announced in Oct 2000.

Stock Forecast:
After showing 250.65 Cr. of sales and 7.94% of quarterly net profit, there have been multiple ups and downs in the Gufic BioSci stock prices in the past few weeks. For example, Gufic BioSci stock price on 5th of June 2026 was around Rs. 369.95. Gufic BioSci share price now stands at an average of Rs. 371.25. Judging by last week's performance, stock is in down trend.

Gufic BioSci has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Gufic BioSci share.

Historical Prices and Performance:
Gufic BioSci, incorporated in 1984 is a Small Cap company (with a market cap of Rs. 3722.99) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Gufic BioSci stock was 9.65%, 11.58%, 16.17%, 22.91% and 35.61% respectively.
The Gufic BioSci share gave a 3 year return of 80.53% as compared to Nifty 50 which gave a return of 26.99%.
Gufic BioSci announced 10.0% final dividend on September 22, 2025.

Key Metrics:
PE Ratio of Gufic BioSci is 55.16
Prices/Sales Ratio of Gufic BioSci is 2.92
Price/Book Ratio of Gufic BioSci is 5.33

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Gufic BioSci, major competitors and peers include Orchid Pharma, Gujarat Themis, IOL Chemicals and RPG Life Sci. As of Dec 2025, the dividend yield of Gufic BioSci stands at 0.03% while Orchid Pharma, Gujarat Themis, IOL Chemicals and RPG Life Sci stand at 0.0%, 0.17%, 0.74% and 1.08% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 55.16 and 5.33 respectively.

Leadership of Gufic BioSci :
Ami N Shah is Co. Secretary & Compl. Officer
Devakinandan B Roonghta is Chief Financial Officer
Jayesh P Choksi is Chairman & Managing Director
Pranav J Choksi is WholeTime Director & CEO
Pankaj J Gandhi is Whole Time Director
Anu S Auora is Independent Director
Kamal K Seth is Independent Director
Akshya Kumar Mahapatra is Independent Director

Industry

Pharma - Indian

Key Indices Listed On

BSE SmallCap, BSE Healthcare, BSE AllCap, BSE Next 250 Microcap, BSE NEXT 500

Address

37, First Floor,Kamala Bhavan II,Mumbai, Maharashtra - 400069

Contact

corporaterelations@guficbio.com

http://www.gufic.com

PE Ratio(x)	57.98
EPS - TTM(₹)	6.40
MCap(₹ Cr.)	3,722.99
MCap Rank	66
PB Ratio(x)	5.49
Div Yield(%)	0.03
Face Value(₹)	1.00
52W High(₹)	407.85
52W Low(₹)	268.00
MCap/Sales	2.92
Beta(1 Month)	0.78
BV/Share(₹)	66.31

PE Ratio(x)	57.92
EPS - TTM(₹)	6.40
MCap(₹ Cr.)	3,718.98
MCap Rank	66
PB Ratio(x)	5.28
Div Yield(%)	0.03
Face Value(₹)	1.00
52W High(₹)	409.00
52W Low(₹)	267.50
MCap/Sales	2.92
Beta(1 Month)	0.81
BV/Share(₹)	66.31

1 Day	5.12%
1 Month	25.23%
3 Months	29.18%
1 Year	-0.42%
3 Years	80.53%
5 Years	98.64%

1 Day	4.75%
1 Month	24.49%
3 Months	29.35%
1 Year	-0.5%
3 Years	79.59%
5 Years	98.47%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Gufic BioSciences Share Price

Key Metrics

Gufic BioSci share price insights

Gufic BioSci Share Price Returns

Gufic BioSci Share Recommendations

News & Analysis

Share Analysis

Unlock Stock Score, Analyst' Ratings & Recommendations

Financials

Technicals

Peer Comparison

Shareholding Pattern

Mutual Funds Ownership

ICICI Pru Multicap Direct-G

SBI Healthcare Opportunities Direct-G

Bank of India Small Cap Direct-G

Gufic BioSci Top Searches

Corporate Actions

About Gufic BioSci

Executive Leadership

Auditors

FAQs about Gufic BioSci share

Top Gainers

Top Losers

Equity Quick Links

More from Markets

Trending in Markets

Browse Companies

Popular Categories

Hot on Web

In Case you missed it

Top Searched Companies

Latest News